35 results about "Folic Acid Derivative" patented technology

Disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein an amide bond is not used. The compound has chemical stability and adequate drug release rate in the living organism. Specifically disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein a substituent represented by formula (I) is bonded to a carboxy group of a block copolymer which is composed of a polyethylene glycol and a polymer having a carboxy group in a side chain, or a pharmacologically acceptable salt thereof.

[In the formula, A represents a monocyclic or fused aromatic group; G represents an optionally substituted (C1-C6) alkylene group; Y represents a hydrogen atom or a substituent; and E represents a residue of folic acid or a folic acid derivative.]

The invention discloses a method for measuring the content of total folic acid and derivatives thereof in vegetables synchronously and quantitatively, which comprises the following steps of: 1) extracting folic acid in the vegetables; 2) adding mouse serum conjugase into the obtained vegetable folic acid extract, incubating and centrifugating to obtain vegetable folic acid deconjugation extract; 3) performing solid phase extraction on the vegetable folic acid deconjugation extract and purifying; 4) separating four folic acid derivatives comprising tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, 5-formyl-tetrahydrofolic acid and the folic acid in the vegetables by using a chromatographic column; and 5) measuring the folic acid quantitatively. By the method, the content of the total folic acid and different folic acid derivatives can be measured synchronously.

The invention provides a composition for a skin-care product. The composition comprises the following components in parts by weight: 0.001-1 part of folic acid and/or folic acid derivative, 0-5 parts of sturgeon fish roe extract, 0-8 parts of pearl extract, and 0-15 parts of caprylic/capric triglyceride; and not all ofthe contents of the sturgeon fish roe extract, the pearl extract and the caprylic/capric triglyceride are 0. Compared with the prior art, the composition provided by the invention has the advantages that by combination of the folic acid and/or folic acid derivative with one or more of the sturgeon fish roe extract, the pearl extract and the caprylic/capric triglyceride, the synergisticeffect can be achieved and the whitening and anti-ageing effects for the skin can be improved; since the sturgeon fish roe extract, the pearl extract and the caprylic/capric triglyceride have the effects of removing free radicals and filtering ultraviolet rays, the light-heat stability of the folic acid can be enhanced, the stability of the content of the folic acid can be maintained and the acting time of the skin-care composition can be prolonged.

The invention relates to a synthesis method of a highly specific folic acid complete antigen and an application of the folic acid complete antigen and belongs to the technical field of biochemical industry. The synthesis method disclosed by the invention comprises the steps of adding 6-aminocaproic acid and water-soluble carbodiimide into a vector protein solution and then reacting at a room temperature and carrying out dialysis to obtain a vector protein B modified by a linker arm, dissolving folic acid(N-{4-[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methylamino]benzoyl}-L-glutamic acid) in dimethyl sulfoxide, adding dicyclohexyl carbodiimide and hydroxysuccinimide, reacting to obtain a folic acid derivative and then coupling the folic acid derivative with an amino group on the linker arm of the vector protein B to obtain the complete antigen. The results show that the titer of the antiserum obtained by immunizing animals with the antigen disclosed by the invention reaches up to 81000, the detection limit is 0.042ng/mL, and the half-inhibitory concentration is 0.3ng/mL. The produced antibody has high specificity and high sensitivity. The antigen or antibody disclosed by the invention is used for preparing an immunoaffinity column, establishing an enzyme linked immunosorbent assay method and colloidal gold strip rapid detection method and detecting the residue of folic acid.

The invention relates to the technical field of medical analysis, in particular to a folic acid detection kit and a folic acid detection method. The kit comprises a magnetic particle suspension coatedwith a folic acid derivative, enzyme-labeled folic acid binding protein, a sample treatment solution and a chemiluminescent substrate, and the sample treatment solution comprises a sample treating fluid 1, a sample treating fluid 2 and a sample treating fluid 3. According to the kit, a specific sample treatment solution is adopted to treat a sample to be detected, folic acid and protein can be mildly separated, protein precipitation is not generated in the detection process, horse radish peroxidase is not damaged, a detection result is high in precision, the correlation with a Rogowski kit ishigh, and the detection result is accurate and reliable; and the detection speed is high, the result can be obtained within 40 minutes, and the kit is suitable for clinical detection of folic acid content.

This invention relates to an oral stabilized modified release pharmaceutical dosage form containing L-methylfolate calcium, which is primarily absorbed from proximal small intestine via a saturable human proton-coupled folate transporter (h-PCFT) mediated transport intended as monotherapy for the treatment of patients with MDDs and/or diagnosed with dysthymia, schizophrenia, or degenerative dementia of the Alzheimer type.

The invention discloses a human epithelial tissue cancer cell detection reagent and a preparation method and application thereof. The human epithelial tissue cancer cell detection reagent is preparedfrom the raw materials in proportions as follows: 0-96 parts of dimethyl sulfoxide by volume, 0-6 parts of a folic acid derivative by weight, 0-3 parts of methylene blue by weight, 0-10 parts of acetic acid by volume, 0-6 parts of ascorbic acid by weight, 0-10 parts of cyclodextrin by weight, 0-10 parts of zinc powder by weight and 0-3 parts of an antioxidant by weight. The invention further provides the preparation method and application of the human epithelial tissue cancer cell detection reagent. The human epithelial tissue cancer cell detection reagent can effectively detect epithelial tissue tumor cells, and has good specificity, high sensitivity and a good application prospect.

The invention relates to a sulfhydrylated folic acid and a preparation method thereof, and belongs to the field of organic synthesis technology. The preparation method comprises a step of oxidizing a sulfhydryl group in a sulfhydryl compound comprising two functional groups (a hydroxy group and a sulfhydryl group) into a disulphur bond to obtain a multifunctional disulphur compound; a step of subjecting the disulphur compound and folic acid (FA) to an esterification reaction; and a step of breaking the disulphur bond by using a reductant to prepare a folic acid derivative containing a free sulfhydryl group. The folic acid derivative can be combined with metal nanoparticles by forming a firm sulphur-metal bond (S-Me), and therefore surface modification of the folic acid to the metal nanoparticles is produced. The sulfhydrylated folic acid and the preparation method have advantages of simple preparation technology and low cost. The structural formula of the sulfhydrylated folic acid is shown as the following formula.

This invention provides a process for efficient production of folic acid derivatives suitable for forming conjugates of anticancer drug with folic acid. It discloses a process comprising a step of reacting 2-amino-protected pteroylimidazole with γ-lower alkyl glutamate; and a step of reacting the resulting product with an amino compound having a reactive group which is readily reactable with a functional group of the drug.

The present invention provides, for example, a method of inhibiting aggregation of complex particles in which a drug is adhered to lead particles, characterized by containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant in the lead particles. Further, it provides, for example, a method of producing the complex particles in which a nucleic acid as a drug or a drug is adhered to lead particles, comprising the step of dispersing or dissolving the nucleic acid as a drug or the drug and an adhesion-competitive agent so as to be contained in a liquid in which the lead particles containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant are dispersed, thereby allowing the nucleic acid as a drug or the drug and the adhesion-competitive agent adhered to the lead particles.

The invention discloses a pharmaceutical composition, a compound preparation as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises the following components in any ratio: a component A: at least one of dextromethorphan or pharmaceutically acceptable salts of dextromethorphan; a component B: at least one of bupropion or medicinal salt of bupropion; component C: at least one of folic acid or folic acid derivatives; and a component D: at least one of methyl donors. The mass ratio of the component A to the component B to the component C to the component D is (1-100):(1-150):(0.1-100):(5-1000). All the components of the pharmaceutical composition can generate a synergistic effect, and the pharmaceutical composition can effectively inhibit over-activation of an NMDA receptor, inhibit reuptake of 5-HT and/or NE and effectively relieve depression.

The invention belongs to the technical field of chemical compounds, and relates to a texaphyrin-folic acid conjugate as well as a preparation method and application thereof, wherein the texaphyrin-folic acid conjugate comprises texaphyrin, a texaphyrin derivative or a conjugate formed by combining a texaphyrin homolog with folic acid or an O-(alkylamino) diaminophenol derivative of a folic acid derivative through a covalent bond. The texaphyrin-folate conjugate or the texaphyrin-folate nano-particles disclosed by the invention are applied to treatment comprising radiosensitization, radiation therapy and photothermal therapy. The texaphyrin-folic acid conjugate also can be used for medical imaging comprising MRI, two-photon, SPECT, PET, CT, fluorescence and ultrasound.

The invention discloses a deoxyglucose modified folic acid derivative as well as synthesis and an application thereof, and the derivative is a novel compound-FA-2-DG formed by combining folic acid anddeoxyglucose in a chemical bond manner. In the derivative, aminoethanol is used as a connecting arm between folic acid and deoxyglucose, and carboxyl of folic acid is connected with amino of aminoethanol to form an amido bond; hydroxyl of the aminoethanol is connected with hydroxyl of the deoxyglucose to generate glycosidic bonds. The connection mode does not destroy the structures and functionsof the folic acid and the deoxyglucose; meanwhile, a distance between two molecules of folic acid and deoxyglucose can be increased through the introduced connecting arms of the two carbon atoms, themethod is more suitable for hydrolysis of glycosidase, and deoxyglucose with anti-tumor activity is released. The derivative FA-2-DG can be used as a drug plastid for drug loading based on the structural characteristics of the derivative FA-2-DG.